Aortic Balloon Counterpulastion in Myocardial Infarction Related Shock
Launched by MARTIN-LUTHER-UNIVERSITÄT HALLE-WITTENBERG · May 3, 2007
Trial Information
Current as of August 25, 2025
Completed
Keywords
ClinConnect Summary
Patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) with cardiogenic shock (CS) are often treated with Intra-aortic balloon pump counterpulsation (IABP) although the evidence to support this is limited. We conducted a prospective, randomised clinical trial, of IABP as an addition to PCI centred therapy, in patients with AMI complicated by CS.
45 patients with AMI and CS undergoing PCI were randomised to care with or without IABP. Over 4 days, APACHE II scores, haemodynamic parameters, inflammatory markers and BNP levels were collected to asses...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute myocardial infarction
- • Cardiogenic shock
- Exclusion Criteria:
- • Absent peripheral pulses
- • Mechanical complications of myocardial infarction
About Martin Luther Universität Halle Wittenberg
Martin-Luther-Universität Halle-Wittenberg (MLU) is a prestigious research institution located in Halle, Germany, renowned for its commitment to advancing scientific knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, MLU emphasizes rigorous research methodologies and ethical standards, fostering collaboration among interdisciplinary teams to address critical health challenges. The university's extensive network of researchers and clinicians enables the development and execution of high-quality clinical trials aimed at improving patient outcomes and contributing to the global body of medical research. Through its dedication to excellence, MLU plays a pivotal role in translating scientific discoveries into tangible healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halle (Saale), Saxony Anhalt, Germany
Patients applied
Trial Officials
Michael Buerke, MD
Study Chair
Martin Luther University
Roland Prondzinsky, MD
Principal Investigator
Martin Luther University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials